当前位置: X-MOL 学术JAMA Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
JAMA Neurology ( IF 20.4 ) Pub Date : 2021-11-01 , DOI: 10.1001/jamaneurol.2021.3126
Vincent Planche 1, 2 , Nicolas Villain 3, 4
Affiliation  



中文翻译:

美国食品和药物管理局批准 Aducanumab - 淀粉样蛋白负载是阿尔茨海默病临床试验的有效替代终点吗?

更新日期:2021-09-13
down
wechat
bug